CMA consults on bipolar drug commitments

Essential Pharma has promised to continue supplying a bipolar drug to UK patients, likely addressing the UK competition authority’s concerns that it abused its dominance by planning to withdraw the medication from the national market.


Get unlimited access to all Global Competition Review content